Erythromycin and its fourteen-member macrolide analogues have attracted attention for their efficacy (Eur Respir J 1998;12:57-63) 
Macrolide antibiotics are widely used in the treatment experimental work it has been shown to play a key role as a mediator of airway inflammation. A considerable of infection. They show broad spectrum antibacterial activity against Gram positive bacteria-for example, increase in the concentration of endothelin-1 in bronchoalveolar lavage (BAL) fluid of the rat occurred Streptococcus pneumoniae-and intracellular bacteriafor example, Mycoplasma pneumoniae, Chlamydia and during the early phase of experimental inflammation 8 and this was associated with a rise in the total cell, Legionella species-and combine this with good tissue penetration. It has been known for many years that eosinophil, and neutrophil counts. Treatment with an endothelin-1 receptor antagonist inhibited the increase macrolide antibiotics have an effect on host cell function as well as an antimicrobial effect. Erythromycin and in BAL fluid eosinophils and reduced the inflammatory reaction in the lung tissue. Bronchial smooth muscle troleandomycin were shown to improve the clinical status of patients with steroid dependent asthma over cells have been shown to possess specific binding sites for endothelin-1 9 and the bronchial epithelial cells of 20 years ago 1 and, more recently, long term low dose erythromycin has been shown to reduce bronchial hyperasthmatic patients express preproendothelin-1 mRNA and release large amounts of biologically active endoreactivity. 2 However, the mechanisms by which these effects occur have remained obscure. In the Introductory thelin-1. 10 Corticosteroids have been shown to reduce the production of endothelin-1 and, for the first time, Article by Takizawa et al erythromycin and clarithromycin have been shown to suppress endothelin-1 this effect has been shown by macrolides. In this study a clinical role for endothelin-1 as a expression and release by human bronchoepithelial cells which may provide new insight into how this effect is bronchoconstrictor was suggested by a negative correlation with peak expiratory flow rate; surprisingly, no achieved. 3 Endothelin-1, a polypeptide, is the most potent vasorelationship was found with forced expiratory volume in one second (FEV 1 ) but the number of subjects studied constrictor known 4 and also has potent bronchoconstrictor effects. 5 It has been reported to stimulate was small. A number of antimicrobial and anti-asthma drugs were also tested but inhibition of endothelin-1 mucus secretion 6 and to cause mucosal oedema. 7 In Table 1 Macrolides  Table 2 Anti-inflammatory mechanisms shown for  macrolides   Ring structure  Name  Mechanism  References  14-membered  Erythromycin, clarithromycin, roxithromycin,  dirithromycin  Reduced endothelin-1  3  15-membered  Azithromycin  Inhibition of neutrophil oxidant burst  15, 16, 17, 18, 19, 31  16-membered  Josamycin, spiramycin  Inhibition of neutrophil chemotaxis  13, 14, 15, 20, 29  Reduced production of IL-6, IL-8 and IL-1 20, 21, 22, 32, 33, 34 Reduced soluble intercellular adhesion 20 molecule 1 (sICAM-1) Reduced production of TNF-22
release was found to occur only with the 14-membered
Suppression of granulocyte-macrophage 21 colony stimulating factor ring macrolides erythromycin and clarithromycin. InReducted defensin production 32
terestingly, no such effect was seen with josamycin, a 16-membered ring macrolide, or with FK506 (table 1) . An effect on endothelin-1 is one of the most recently described of a number of anti-inflammatory properties induced by intratracheal instillation of lipopolyshown by the 14-membered ring macrolides (fig 1) . saccharide 13 or aerosolised Proteus mirabilis and StaphyThe following sections describe some of these mechlococcus aureus. 14 Thus, an anti-inflammatory effect has anisms and lead on to a description of other studies of been repeatedly demonstrated in animal models with the use of macrolides in asthma and other conditions roxithromycin, seemingly more potent than azithrocharacterised by inflammation.
mycin and clarithromycin, with erythromycin having the least effect. It has been postulated that this could be due to better cell penetration by the newer macrolides Macrolides and the inflammatory response than by erythromycin. The inflammatory process is multifactorial and macrolides have been shown to act in a number of different ways, their effects being demonstrated in various animal
Macrolides and the neutrophil oxidant burst models (table 2). Oedema produced by the injection of Reactive oxidant products of neutrophils are known to carrageenin into the paw of a rat can be suppressed by damage tissue and the intracellular accumulation of pretreatment of the animal with a macrolide. 11 Roxmacrolides may limit their production, although data ithromycin has been shown to reduce oedema formation on this are conflicting. Lambro et al 15 have shown that with an effect almost equal to that of the non-steroidal only roxithromycin strongly decreased the polyanti-inflammatory drug nimesulide, while azithromycin morphonuclear neutrophil (PMN) oxidative burst as and clarithromycin showed lesser anti-inflammatory assessed by luminol amplified chemiluminescence, effects. Roxithromycin has been further evaluated in a superoxide anion generation, and myeloperoxidase mevariety of rat models including poly--arginine induced diated iodination of proteins. This effect was noted to paw oedema, croton oil inflamed ear assay, and invary significantly between individuals and may relate to traperitoneal polyester sponge granuloma. 12 It produced the high concentration of roxithromycin achieved within a marked anti-oedema effect similar to that of indothe neutrophil. Anderson et al 16 found that both methacin in poly--arginine assay, significant inhibition erythromycin and roxithromycin selectively inhibited of croton oil induced inflammation in the ear, but failed superoxide generation by activated neutrophils. Hand to reduce the development of granuloma induced by et al 17 observed that roxithromycin which readily enters implanted polyester sponges. Pretreatment with erythe phagocyte was an efficient inhibitor of the thromycin decreased neutrophil counts in BAL fluid PMN superoxide generation stimulated by formylfrom the lungs of mice in which inflammation had been methionyl-leucyl-phenylalanine (FMLP) and concanavalin A. Clearly, it would be of interest to minimise the oxidative response of human PMNs whilst preserving their bactericidal and phagocytic functions.
Macrolides and neutrophil chemotaxis
Stimulation of neutrophil migration has been described in two studies. 16 18 In one, adult volunteers were given a single oral dose of 500 mg erythromycin stearate and a significant increase in PMNL migration in response to a leucocyte attractant was observed at 90 minutes. Conflicting data were produced in a study by Torre et al 19 who observed decreased PMN chemotaxis following the ingestion of erythromycin, josamycin, miokamycin, roxithromycin, and rokitamycin for four days by adult volunteers. Reduction in chemotaxis was observed by other workers, 13 14 raising concerns that the bactericidal effects of these antibiotics might be reduced. However, the relevance of these findings in the clinical setting is not yet known.
Macrolides and cytokine production
Cytokines are small proteins involved in the or- shown to suppress the production of IL-6 and IL-8 and granulocyte-macrophage colony stimulating factor, in addition to inhibiting neutrophil adhesion to epithelial Macrolides and diffuse panbronchiolitis (DPB) cells. 21 Erythromycin also caused a dose dependent A clinical role for macrolides, which is not due to a decrease in heat killed Streptococcus pneumoniae (HKSP) direct antimicrobial effect, is perhaps best shown in induced production of TNF-and IL-6 in human whole DPB. This disease is characterised by chronic bronchial blood in vitro. 22 The production of IL-1, IL-12, and sepsis and airflow obstruction with chronic inflamgamma interferon was only affected at the highest conmation of the respiratory bronchioles, stenoses, and centration of erythromycin. The production of TNFobstruction. Initial infections are with H influenzae, Strep and IL-6 in whole blood obtained from healthy subjects pneumoniae, and Staph aureus, and eventually patients after a 30 minute infusion of 1 g of erythromycin was become colonised with Pseudomonas aeruginosa. Death lower after ex vivo stimulation with HKSP than blood due to respiratory failure occurs after repeated cycles of drawn before infusion. Effects on the cytokine pathways infection. The disease occurs commonly in Japan with are complex but reduction in the pro-inflammatory occasional cases reported in Italy and North America. cytokines in experimental models provides some insight
The prognosis of DPB has been dramatically improved into how these effects might be achieved in vivo.
in recent years by the use of erythromycin and other macrolide antibiotics in this condition. In 1984 the five year survival rate was only 26% in cases with P aeruginosa and 55% for all other types of DPB. Since erythromycin Macrolides and asthma has become widely used, the 10 year survival for all Macrolides have been shown to affect bronchial types of DPB has increased to 94%. hyperresponsiveness by a non-antibiotic mechanism.
The clinical efficacy of erythromycin in this condition Rosenberg et al 23 described a patient with corticosteroid was first noticed in 1982 and has since been confirmed dependent asthma in whom the addition of daily troby clinical trials 27 28 but the mechanism of action is leandomycin allowed corticosteroids to be weaned withstill unknown. Studies indicate a crucial role for the out clinical deterioration (table 3) . Erythromycin has polymorphonuclear leucocyte in the pathogenesis with been shown to reduce the severity of bronchial hyperinflux of these cells into the airways and the production responsiveness in adult asthmatics who were not corticoof oxidants and proteolytic enzymes producing insteroid dependent 24 ; 200 mg of erythromycin three times flammatory change. Bronchoalveolar lavage (BAL) fluid a day given over a 10 week period resulted in a significant from sufferers has demonstrated increased numbers of increase in the PC 20 in both atopic and non-atopic neutrophils, neutrophil derived elastolytic-like activity, patients, supporting the observation of an improvement IL-8, IL-1 , and leukotriene B4 (LTB4). After treatin asthma control by macrolides by workers in the early ment with erythromycin the number of neutrophils and 1970s. 1 The interaction of erythromycin with theoamount of neutrophil derived elastolytic-like activity in phylline, reducing its clearance and increasing plasma BAL fluid has been shown to decrease significantly with theophylline levels, could partly explain the beneficial a coincident improvement in lung function. 29 This was effects of erythromycin. However, in this study 600 mg also described by Kadota et al 13 who found increased erythromycin daily produced no change in serum theonumbers of neutrophils and neutrophil chemotactic phylline levels. A further study was performed on chilactivity in the BAL fluid of patients compared with dren with asthma using roxithromycin, an antibiotic with normal subjects which was reduced by erythromycin little effect on the pharmacokinetics of theophylline. 25 treatment; this was also found in an animal model. Again, the PC 20 significantly increased with 150 mg Benefit is not confined to erythromycin and has been roxithromycin daily after four and eight weeks of treatdemonstrated with other 14-membered macrolides. An ment. This study also reported no change in the liver efficacy of 79% for erythromycin (400 mg or 600 mg), enzymes SGOT and SGPT or morning cortisol levels 86% for roxithromycin (150 mg or 300 mg), and 67% and concluded that roxithromycin did not affect corticofor clarithromycin (200 mg or 400 mg) taken daily for steroid metabolism.
at least two months has been reported. 30 Azithromycin, Reduced production of reactive oxygen species by a 15-membered macrolide, has also been shown to polymorphomuclear leucocytes or an effect on neutrobe effective. 31 Defensins, antimicrobial and cytotoxic phil chemotaxis or cytokine production may be involved.
peptides which occur in high concentrations in the BAL Decreased production of neutrophil chemotactic fluid of patients with DPB are reduced with macrolide lymphokines has also been postulated.
14 Experimentally, treatment 32 and several studies have shown a reduction erythromycin has been shown to reduce the electrical in levels of IL-8 and IL-1 . [32] [33] [34] Reduced adhesion field stimulation induced contraction of isolated human molecule macrophage activating complex 1 (MAC-1) on bronchial strips in a dose dependent fashion, suggesting peripheral blood neutrophils has also been shown to occur that macrolides may inhibit the cholinergic neuroafter macrolide therapy. 33 Sixteen-membered macrolides effector mechanism possibly by reducing acetylcholine including josamycin are not beneficial in DPB. release at nerve terminals. 26 However, the effect on endothelin-1 described in the Introductory Article is likely to be another important mechanism by which Macrolides and bronchiectasis/cystic fibrosis The dramatic effect of macrolides on the prognosis of bronchoconstriction is reduced. DPB has led to trials in other conditions characterised cyte infiltration around small airways which gradually developed into granuloma-like infiltration containing by chronic bronchial sepsis including bronchiectasis macrophages. The state of antigen excess resulting from and cystic fibrosis. Both conditions are associated with persistent colonisation of mucoid alginate producing P copious sputum production, rhinosinusitis, progressive aeruginosa may generate an immune complex in the airway destruction, and chronic P aerurginosa infection host. The levels of serum immune complexes in patients of the airways. A double blind, placebo controlled trial with DPB have been positively correlated with clinical of low dose erythromycin in bronchiectasis has recently symptoms. These immune complexes deposit on lung been published. 35 Erythromycin was given to 11 patients tissue and stimulate neutrophil chemotaxis. 38 Long term with bronchiectasis in a dose of 500 mg twice daily for treatment with clarithromycin has resulted in most cases an eight week period and FEV 1 , forced vital capacity in a decrease in serum immune complexes and an (FVC), and sputum volume over 24 hours were sigimprovement in clinical symptoms. 28 Erythromycin, nificantly improved compared with placebo. However, clarithromycin, and azithromycin have been shown to no parallel improvement in sputum pathogens, leucocytes, be effective inhibitors of antigen-antibody reaction in IL-1 and IL-8, TNF-or LTB4 was found. Eryvitro but not 16-membered macrolides or cethromycin is unlikely to be bactericidal in view of the low phalosporins. Long term treatment with azithromycin dosage and poor penetration into the bronchial tree, and has been shown to improve lung function in patients the authors postulate that inhibition of glycoconjugate with cystic fibrosis. 39 release and chloride secretion by airway epithelium and Combining macrolides with antipseudomonal antimacrophage mucus secretagogue production might result biotics may be more effective than administering antiin decreased sputum water content and volume. Airway pseudomonal antibiotics alone. 28 In vitro incubation of responsiveness in bronchiectasis has also been shown to biofilm P aeruginosa with twice the minimum bactericidal improve with long term, low dose macrolide adconcentration of ciprofloxacin resulted in 85% of bacteria ministration. Roxithromycin was given to 13 children remaining viable. However, when clarithromycin or with increased airway responsiveness and bronchiectasis azithromycin was added, the bactericidal effect of ciproand a group of 12 controls received placebo. 36 Methafloxacin was far greater. This offers new prospects for choline challenge tests were performed at baseline and clinical trials of these antibiotics in combination in patients after 12 weeks. The PC 20 increased significantly in the with cystic fibrosis and bronchiectasis. roxithromycin group while no change was seen in the placebo group. In addition, improvement in sputum features was noted after six weeks in the treatment group.
Atheroma, arthritis, and cancer That macrolides might be efficacious in these conAn effect of macrolides has been described in each of ditions by a non-bactericidal effect on P aeruginosa these conditions. Whether the mechanism relates to its has been postulated by Howe and Spencer. 37 Diffuse anti-inflammatory effect, antimicrobial effect, or some panbronchiolitis, bronchiectasis, and cystic fibrosis are other effect remains to be discovered. The development all associated with chronic P aeruginosa infection and of atheroma has been linked to chronic chlamydial inhibition of this organism could be a mode of action.
infection. [40] [41] [42] [43] Two clinical trials have been undertaken Two mechanisms by which macrolides might be effective of macrolide therapy as secondary prevention in patients are proposed: an effect on the immune system to modify with known coronary artery disease. In the first by the inflammatory response to infection or a direct effect Gupta et al 44 220 male survivors of acute myocardial on P aeruginosa to decrease its virulence. In addition to infarction were screened for IgG antibody to Chlamydia the effects on the immune system described above, pneumoniae by microimmunoflorescence. Those with macrolides inhibit endotoxin A, total protease, elastase, titres of >1/64 on two consecutive occasions were ranphospholipase C, DNase, lecithinase, gelatinase, lipase, domised to receive azithromycin 500 mg daily for three pyocyanin and motility, all virulence factors associated days and repeated at three months or placebo. Patients with P aeruginosa infection. Strains of P aeruginosa found were followed for a mean of 18 months. A five fold in these conditions produce a mucoid alginate by which reduction in adverse cardiovascular events was found they closely adhere to the airway surface. In this "bio-(p=0.03) in the azithromycin treated group compared film" the bacteria are resistant to attack by antibacterial with placebo. A second study by Gurfinkel et al 45 enrolled agents and interaction with neutrophils. The alginate 202 patients with unstable angina or non-Q wave myoworks as an antigen and serum titres of anti-alginate cardial infarction. Patients were randomised to receive antibody IgG and IgA are significantly higher in Pseudoroxithromycin 150 mg twice daily for 30 days or placebo, monas positive patients with DPB than in Pseudomonas independent of C pneumoniae serostatus. They were negative patients. In experimental models the alginate followed for six months and the primary end point was a composite of three outcomes-cardiac death, acute induced antigen-antibody reaction resulted in lympho-LEARNING POINTS * Multiple in vitro and in vivo anti-inflammatory effects of macrolides have been demonstrated. * Anti-inflammatory effects appear to be limited to macrolides with 14-membered and 15-membered ring structure.
man has yet to be demonstrated.
Clin Immunol 1995;95:853-9.
A possible role for macrolides in arthritis has been 
